The FDA participant table for the TEMPO Digital Health Devices Pilot lists Dexcom and its Glucose Health Program. It also lists Cadence Solutions and HypertensionOS. Those names make the pilot relevant to digital health operators, but the official wording sets an important limit: selection is not the same as FDA approval or clearance.
The FDA says it has not yet evaluated the effectiveness of the selected devices for the intended uses for which they are participating in the pilot. A responsible reading therefore begins with the pilot structure, not with a marketing shortcut.
What TEMPO is designed to collect
According to the FDA, participating manufacturers will collect, monitor, and report real world data related to the intended uses of their devices. The data collection is tied to the pilot and to the care context described by the agency.
This creates a pathway for learning from use in practice. It does not create a general finding that every selected product is effective for every patient, setting, or workflow. The monitored use and the evidence collected inside the pilot remain part of the meaning.
Why selection is not authorization
The participant page explicitly separates selection from an effectiveness evaluation. That distinction matters for clinics, technology vendors, and business teams that may see a familiar company name and assume a broader regulatory conclusion.
The safer language is precise: a company and device program appear in the official TEMPO participant table. Any statement about authorization, effectiveness, or a particular intended use requires its own supporting FDA record.
The ACCESS boundary
The FDA explains that a manufacturer may request enforcement discretion for certain requirements when a device is offered to or by CMMI ACCESS participants for a covered intended use. This is a bounded pilot condition, not a universal permission.
Interested in implementing similar AI solutions? Discover how PATech Labs can help your business leverage cutting-edge artificial intelligence.
Learn About Our Services| Check | Why it matters |
|---|---|
| User and setting | The pilot condition is tied to CMMI ACCESS participants and a covered intended use. |
| Use outside ACCESS | The FDA says the same intended use in other contexts falls outside TEMPO. |
A path toward a future submission
The agency expects participating manufacturers ultimately to seek appropriate marketing authorization. The FDA says the pilot data may be used together with additional supporting information in a future marketing submission.
That sequence explains why real world monitoring is central to the story. Participation supports evidence development, while an eventual authorization remains a separate regulatory step.
Questions a healthcare operator should ask
- Which device is named?
- Which intended use is covered?
- Does the use involve ACCESS participants?
- Which FDA record supports the exact wording?
Also check the FDA participant page again before publication or procurement. The agency notes that the table can change as additional manufacturers are selected, so an older screenshot should not be treated as a permanent participant list.
How the operational lesson connects
PATech Voice Front Office is a service for organizing inbound conversations and business workflows. It does not establish FDA status, clinical effectiveness, reimbursement, or eligibility for TEMPO.
The practical lesson is to keep evidence, setting, and claim language together. TEMPO is a structured pilot for collecting real world data in a defined context, not a substitute for the authorization record that may come later. A precise description may feel less dramatic, but it gives healthcare decision makers a claim they can verify against the agency record.